HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress-Reference-Cited by-同舟云学术

HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress

Published:2018-09-05 Issue:21 Volume:78 Page:6196-6208
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Nichols Brandt A.,Oswald Nathaniel W.,McMillan Elizabeth A.,McGlynn Kathleen,Yan Jingsheng,Kim Min S.,Saha Janapriya,Mallipeddi Prema L.,LaDuke Sydnie A.,Villalobos Pamela A.,Rodriguez-Canales Jaime,Wistuba Ignacio I.,Posner Bruce A.,Davis Anthony J.,Minna John D.^ORCID,MacMillan John B.^ORCID,Whitehurst Angelique W.

Funder

HHS | NIH | National Cancer Institute (NCI)

Tobacco-Related Disease Research Program (TRDRP)

U.S. Department of Defense (DOD)

American Association for Cancer Research (AACR)

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

Cancer Prevention and Research Institute of Texas (CPRIT)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities;NAR Cancer;2024-04-08

3. A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors;Oncogene;2024-03-11

4. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer;Molecular Therapy: Oncology;2024-03

5. Structural and biochemical insights into the interaction mechanism underlying HORMAD1 and its partner proteins;Structure;2023-12